JP2008540438A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008540438A5 JP2008540438A5 JP2008510181A JP2008510181A JP2008540438A5 JP 2008540438 A5 JP2008540438 A5 JP 2008540438A5 JP 2008510181 A JP2008510181 A JP 2008510181A JP 2008510181 A JP2008510181 A JP 2008510181A JP 2008540438 A5 JP2008540438 A5 JP 2008540438A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- compound according
- pain
- hydrogen
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 191
- 229910052739 hydrogen Inorganic materials 0.000 claims 52
- 239000001257 hydrogen Substances 0.000 claims 52
- 229910052757 nitrogen Inorganic materials 0.000 claims 35
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 34
- 229910052717 sulfur Inorganic materials 0.000 claims 33
- 125000005842 heteroatom Chemical group 0.000 claims 32
- 229910052760 oxygen Chemical group 0.000 claims 32
- 208000002193 Pain Diseases 0.000 claims 26
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 26
- 229920006395 saturated elastomer Polymers 0.000 claims 26
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 22
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 22
- 239000001301 oxygen Chemical group 0.000 claims 22
- 239000011593 sulfur Chemical group 0.000 claims 22
- -1 1H-benzimidazol-2-yl Chemical group 0.000 claims 20
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 15
- 125000002950 monocyclic group Chemical group 0.000 claims 14
- 125000001931 aliphatic group Chemical group 0.000 claims 12
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 12
- 150000002431 hydrogen Chemical class 0.000 claims 11
- 239000000126 substance Substances 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 10
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 8
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 8
- 208000004296 neuralgia Diseases 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000004429 atom Chemical group 0.000 claims 6
- 229910052731 fluorine Inorganic materials 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 6
- 125000005322 morpholin-1-yl group Chemical group 0.000 claims 6
- 230000001154 acute effect Effects 0.000 claims 5
- 125000002723 alicyclic group Chemical group 0.000 claims 5
- 125000002619 bicyclic group Chemical group 0.000 claims 5
- 229910052794 bromium Inorganic materials 0.000 claims 5
- 229910052801 chlorine Inorganic materials 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 208000021722 neuropathic pain Diseases 0.000 claims 5
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 4
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 4
- 230000001684 chronic effect Effects 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 208000008035 Back Pain Diseases 0.000 claims 3
- 206010019233 Headaches Diseases 0.000 claims 3
- 208000004404 Intractable Pain Diseases 0.000 claims 3
- 206010028836 Neck pain Diseases 0.000 claims 3
- 208000005298 acute pain Diseases 0.000 claims 3
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical group C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 claims 3
- QXNDZONIWRINJR-UHFFFAOYSA-N azocane Chemical group C1CCCNCCC1 QXNDZONIWRINJR-UHFFFAOYSA-N 0.000 claims 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 230000002981 neuropathic effect Effects 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 3
- 208000000003 Breakthrough pain Diseases 0.000 claims 2
- 206010058019 Cancer Pain Diseases 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 208000006561 Cluster Headache Diseases 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 2
- 208000004550 Postoperative Pain Diseases 0.000 claims 2
- 206010059604 Radicular pain Diseases 0.000 claims 2
- 208000008765 Sciatica Diseases 0.000 claims 2
- 208000018912 cluster headache syndrome Diseases 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 2
- 208000009935 visceral pain Diseases 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003011 Appendicitis Diseases 0.000 claims 1
- 208000006820 Arthralgia Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 206010006002 Bone pain Diseases 0.000 claims 1
- 206010064012 Central pain syndrome Diseases 0.000 claims 1
- 206010008479 Chest Pain Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 208000024720 Fabry Disease Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010019909 Hernia Diseases 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- 206010020853 Hypertonic bladder Diseases 0.000 claims 1
- 206010021639 Incontinence Diseases 0.000 claims 1
- 208000007914 Labor Pain Diseases 0.000 claims 1
- 208000035945 Labour pain Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 208000008930 Low Back Pain Diseases 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 208000005890 Neuroma Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 1
- 206010033425 Pain in extremity Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010033647 Pancreatitis acute Diseases 0.000 claims 1
- 208000000450 Pelvic Pain Diseases 0.000 claims 1
- 208000010886 Peripheral nerve injury Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 claims 1
- 206010037596 Pyelonephritis Diseases 0.000 claims 1
- 206010037779 Radiculopathy Diseases 0.000 claims 1
- 206010051496 Rhinalgia Diseases 0.000 claims 1
- 206010040037 Sensory neuropathy hereditary Diseases 0.000 claims 1
- 208000000491 Tendinopathy Diseases 0.000 claims 1
- 206010043255 Tendonitis Diseases 0.000 claims 1
- 206010043269 Tension headache Diseases 0.000 claims 1
- 208000008548 Tension-Type Headache Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 claims 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 210000001015 abdomen Anatomy 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 208000038016 acute inflammation Diseases 0.000 claims 1
- 230000006022 acute inflammation Effects 0.000 claims 1
- 201000003229 acute pancreatitis Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000003725 azepanyl group Chemical group 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 201000001352 cholecystitis Diseases 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 210000001097 facial muscle Anatomy 0.000 claims 1
- 208000037584 hereditary sensory and autonomic neuropathy Diseases 0.000 claims 1
- 201000006847 hereditary sensory neuropathy Diseases 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000003243 intestinal obstruction Diseases 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 208000013465 muscle pain Diseases 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000015706 neuroendocrine disease Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000020629 overactive bladder Diseases 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 208000001297 phlebitis Diseases 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 201000007094 prostatitis Diseases 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 208000005198 spinal stenosis Diseases 0.000 claims 1
- 230000007863 steatosis Effects 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000002123 temporal effect Effects 0.000 claims 1
- 201000004415 tendinitis Diseases 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 1
- 208000004371 toothache Diseases 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 208000026533 urinary bladder disease Diseases 0.000 claims 1
- 208000014001 urinary system disease Diseases 0.000 claims 1
- 0 C*(CCCCC1)C*1NC(C)=O Chemical compound C*(CCCCC1)C*1NC(C)=O 0.000 description 2
- HSECJZOSVXXVAK-UHFFFAOYSA-O CC(C1)CC1N[NH3+] Chemical compound CC(C1)CC1N[NH3+] HSECJZOSVXXVAK-UHFFFAOYSA-O 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67811805P | 2005-05-04 | 2005-05-04 | |
| PCT/US2006/017046 WO2006119390A1 (en) | 2005-05-04 | 2006-05-03 | Pyridines useful as modulators of ion channels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008540438A JP2008540438A (ja) | 2008-11-20 |
| JP2008540438A5 true JP2008540438A5 (https=) | 2009-07-02 |
Family
ID=36879646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008510181A Withdrawn JP2008540438A (ja) | 2005-05-04 | 2006-05-03 | イオンチャネルのモジュレーターとして有用なピリジン |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US7683065B2 (https=) |
| EP (1) | EP1877381A1 (https=) |
| JP (1) | JP2008540438A (https=) |
| WO (1) | WO2006119390A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8101618B2 (en) * | 2005-04-06 | 2012-01-24 | Msd K.K. | 1,4-substituted piperazine derivatives |
| JP5388574B2 (ja) * | 2005-05-31 | 2014-01-15 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネルのモジュレーターとして有用なヘテロ環式類 |
| TW200728258A (en) | 2005-10-10 | 2007-08-01 | Glaxo Group Ltd | Novel compounds |
| TW200730494A (en) | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
| EP1943216B1 (en) | 2005-10-10 | 2010-06-30 | Glaxo Group Limited | Prolinamide derivatives as sodium channel modulators |
| EP2655330B1 (en) * | 2010-12-22 | 2016-02-10 | Purdue Pharma LP | Substituted pyridines as sodium channel blockers |
| ES2912881T3 (es) | 2014-12-23 | 2022-05-30 | Convergence Pharmaceuticals | Procedimiento para preparar derivados de alfa-carboxamida pirrolidina |
| US11192856B2 (en) | 2017-10-05 | 2021-12-07 | Biogen Inc. | Process for preparing alpha-carboxamide pyrrolidine derivatives |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0930302B1 (en) * | 1998-01-16 | 2003-04-02 | F.Hoffmann-La Roche Ag | Benzosulfone derivatives |
| JP4272338B2 (ja) * | 2000-09-22 | 2009-06-03 | バイエル アクチェンゲゼルシャフト | ピリジン誘導体 |
| TW200519094A (en) * | 2003-07-02 | 2005-06-16 | Vertex Pharma | Pyrimidines useful as modulators of voltage-gated ion channels |
| RU2347777C2 (ru) * | 2003-07-03 | 2009-02-27 | Ф.Хоффманн-Ля Рош Аг | Двойные агонисты nk1/nk3 для лечения шизофрении |
-
2006
- 2006-05-03 WO PCT/US2006/017046 patent/WO2006119390A1/en not_active Ceased
- 2006-05-03 EP EP06759012A patent/EP1877381A1/en not_active Withdrawn
- 2006-05-03 JP JP2008510181A patent/JP2008540438A/ja not_active Withdrawn
- 2006-05-04 US US11/418,278 patent/US7683065B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009539988A5 (https=) | ||
| RU2009100159A (ru) | Тиенопирамидины, полезные в качестве модуляторов ионных каналов | |
| EP0600949B1 (de) | Neue 3,5-di-tert.butyl-4-hydroxyphenyl-derivate, verfahren zu ihrer herstellung und arzneimittel | |
| JP2020528889A5 (https=) | ||
| JP2020505376A5 (https=) | ||
| JP2011500598A5 (https=) | ||
| JP2006514006A5 (https=) | ||
| CA3147397A1 (en) | Macrocyclic compounds as sting agonists and methods and uses thereof | |
| JP2018109017A5 (https=) | ||
| JP2008540443A5 (https=) | ||
| EP1539675B1 (en) | Aryl and heteroaryl propene amides, derivatives thereof and therapeutic uses thereof | |
| JP2015522551A5 (https=) | ||
| JP2011510965A (ja) | 高眼圧症の治療のためのジフルオロビフェニルアミド誘導体 | |
| JP2008511670A5 (https=) | ||
| EP2123620A1 (en) | {F-19}-labeled L-Glutamic acid and L-Glutamine derivative (III), use thereof and method for obtaining them | |
| JP2019536821A (ja) | 水溶性アロプレグネノロン誘導体およびその使用 | |
| JP2008540438A5 (https=) | ||
| AU733043B2 (en) | Cyanoguanidines as cell proliferation inhibitors | |
| US6458816B1 (en) | Modified prodrug forms of AP/AMP | |
| US6855695B2 (en) | Water-soluble SHPs as novel alkylating agents | |
| JP7618642B2 (ja) | インターロイキンの調節におけるプロドラッグ | |
| JP2008540665A5 (https=) | ||
| RU2008123811A (ru) | Хиназолины, используемые в качестве модуляторов потенциалзависимых ионных каналов | |
| AU2008236994A1 (en) | Method of treating melanoma | |
| JP2008542377A5 (https=) |